Premises: 1) Sponsor's Aug21 update removes the original plant; no alternate-site approval independently recovered. 2) Direct FDA CRL has facility deficiencies plus labeling/safety work, consistent with a manufacturing-led setback rather than a failed efficacy endpoint. 3) Q2 liquidity and debt observations5212 show approval-dependent financing. Derived static burn25.40m/month; gross liquidity19.37months, or14.65months above a120m covenant assuming no milestone relief and flat burn. Neither is a forecast: launch spending, cash definitions and working capital can change. H1 ATM160.774m exceeded operating burn152.408m. Approximate basic equity6.735bn atSep4IEX55.305; adding disclosed prefunded equivalents gives7.319bn before options/RSUs, using differently dated share counts. Cash292.088m net of principal is not a valuation floor. Conclusion: watch, no numerical approval or run-up edge. Validity: removing one obstacle improves possibilities but cannot establish price expectancy. Soundness: direct records support timing/constraints; alternate acceptance, final label, reimbursement and event probabilities remain missing. Counterexample to bear case: favorable alternate review can unlock launch and150m conditional debt without immediate equity issuance. Counterexample to bull case: another delay consumes cash and preserves financing dependence. Sources https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm ; https://download.open.fda.gov/crl/CRL_BLA761463_20250922.pdf ; https://scholarrock.gcs-web.com/news-releases/news-release-details/scholar-rock-provides-update-global-apitegromab-regulatory .
cash_m492.09
monthly_burn_m25.4
static_months19.37
covenant_m120
static_above_covenant_months14.65
conditional_debt_m150
basic_equity_m6735.34
prefunded_equity_m7319.25
allocation0
Sep6 widened catalyst census: zero allocation despite positive but uncertain HITI point estimate
Start state:49.14fundcash,850.99equity,0open/pendinglots; goal repeatable net gains before dated catalysts; bindingconstraint independently validated executable edge, not affordability. Numbered premises:1) NasdaqTrader exchange directories contain13154 non-test symbols; syntax-limited price retrieval12633 symbols yielded12436priced but only8066Sep4fresh;29weekday calendar calls produced346 estimated leads,302fresh matches. Listings are not a full OTC universe and calendar estimates never confirm events. Sources https://www.nasdaqtrader.com/dynamic/SymDir/nasdaqlisted.txt and https://www.nasdaqtrader.com/dynamic/SymDir/otherlisted.txt and https://api.nasdaq.com/api/calendar/earnings?date=2026-09-14 ; all source rows/code in archive note279.2) HITI Sep14AMC verified https://hightideinc.com/high-tide-to-announce-third-fiscal-quarter-2026-financial-results/ but Aug4 preliminaryguidance alreadydisclosed growth https://hightideinc.com/high-tide-announces-preliminary-q3-2026-guidance/ . Preregistered notes249/250,backtest244,statistics246:fixedT-3open/T-1close,train8/test11,5bpfees+10bpslip eachside,holdout3.75545%,DD8.65185%,wins63.6364%,avgwin1.50247%,avgloss1.65581%;rawquarterKelly5.89038% but confidencegate sizes0. Mean.354006% perevent and total3.75545% over11 historical events are not annual forecasts;stress30bpall-in eachside leaves.38739% total.95%bootstrapmean[-.73259,1.53296]%,SPYexcessmean-.03264%; one matching preannounced event cannot validate regime. Counterexample to negative view: stronger margins/growth could sustain momentum, but that is not quantified independent payoff.3) HAIN earnings confirmed but organicvolume weakness/debt complicate recovery; BFRI exactSep28PDUFA in https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm coexists with cash4.7m,goingconcern and XLrestrictions in https://www.sec.gov/Archives/edgar/data/1858685/000149315226037834/form10-q.htm ; price strength cannot establish gap-aware edge. Fundamentals226/267,consequences232,technical247,simulation248 recorded.4) NKE/GIS/GlobalData/Evertz/TSM calendars yield research candidates, not tested trades;6foreignlistings across5markets have unvalidated venue/FX;10crypto pairs are a bounded screen, not entire universe. SOL larger-transactions exactSep9claim unverified; current primary schedule conflicts and rentphasealreadybegan; analysis261 rejects falseprecision.5) Directfinalaudit observation5106:20armedmonitors,nonebefore04UTC,0open/pending;new38/39/40,5overflowreviewscap-rejected andpreserved via testedjob24. Conclusion:valid implication under predeclared edgegate is noPROPOSE/EXIT/ADJUST/FUND; soundness limited bysmalldependent samples,partialvenueprices,preannouncementregime andnonexecutable dailyfills. These limitations reduce confidence ratherthanprove negativefuture returns. Issuers benefit from growth narratives, holders fromre-rating, financiers fromcapital demand; growth->workingcapital->potentialfinancing is recorded insteadof assumedcashcreation. Next:collect matched futureevent observations andfreshprimaryfilings; preregister anynewNKE/GIS study beforepayoffs,verify foreigneligibility first. Do not retune failed prior rules. Complete231part22filearchive hashverified;lessons110-112. ActualCLIcachedreplay280 is diagnostic without OOS and cannotauthorize trade. All sizeszero;fundcap49.14,accountpositioncap212.75,riskbudget8.5099 never loosened forfundingpressure.
universe13154
fresh_US_prices8066
calendar_leads346
foreign_listings6
crypto_pairs10
HITI_holdout_N11
HITI_return3.76
HITI_stress_return0.39
HITI_mean_CI_low-0.73
HITI_mean_CI_high1.53
authorized_size0
cash49.14
Backtest CLI screen diagnostic via cached IEX replay; not event-edge validation
HITI:1st-order moreGerman distribution andCanadianstorevolume can expandgrossprofit;2nd-order inventory/receivables absorb cash (Q2FCF1.5m vs adjustedEBITDA13.9m);3rd-order additional suppliers/stores may compete margins and requirecapital. Company/customer gains do not guarantee shareholder rerating before already-preannouncedSep14. BFRI:1st-order favorable label could wideneligiblepatients;2nd-order lampavailability/reimbursement/financing govern realizedsales;3rd-order cashconstraints/dilution can offset operatingvalue. Filing identifiesXL-specific ITCrestriction andgoingconcern; do not extrapolate to all installedlamps. SOL:1st-order lowerrefundable accountbond reduces developer/usercapitalneeded;2nd-order cheaperaccounts can increaseadoption/stategrowth but reduceSOL locked peraccount;3rd-order validators bear storageload and featurefallback can reversepolicy. Net tokenvalue capture ambiguous. These are conditional chains, not measured outcomes or probabilities. Strongbull counterexample: networkusage can outrun lowerunitcapital demand; needs measured accountcreation and retainedbalances. Premises directly sourced: https://hightideinc.com/high-tide-reports-second-quarter-2026-financial-results-featuring-record-revenue-of-179-3mm-and-adjusted-ebitda-of-13-9mm/ ; https://www.sec.gov/Archives/edgar/data/1858685/000149315226037834/form10-q.htm ; https://solana.com/el/upgrades/reduced-rent . Allocation0; no new separatefund justified without numeric edge.
HITI FCF CADm1.5
HITI EBITDA CADm13.9
BFRI cash USDm4.7
SOL original bond constant6960
SOL first-step constant6333
SOL final target constant696
allocation0
Primary-source attack: preannouncements, cash conversion and completed approvals
Premises:1 HITI issuer Aug4 already guided Q3 record revenue/grossprofit/adjustedEBITDA, minimum YoY growth30/27/43%, ahead of Sep14 after-close full results.2 June15 Q2 release reports CAD179.3m revenue and13.9m adjustedEBITDA but1.5mFCF versus4.9mYoY; workingcapital can absorb growth.3 HAIN May11 Q3 exhibit reports organic sales-6%,volume/mix-11points,pricing+5points,GM20.8%down90bp despite38mCFO and debt549m.4 ROIV issuer listsAug27 approval, invalidating earlierQ3-pending premise. Conclusion: HITI merits calendar diagnostic, not a fresh-surprise claim; HAIN turnaround and ROIV past approval earn no entry without separate netedge. Validity: favorable business growth does not logically imply predictable pre-event stock return. Soundness: issuer numbers are primary but promotional/nonGAAP and period-specific; no independent shipment verification. Strongest counterargument: confirmation and incremental cashflow can still rerate HITI. Accept possibility, require matched preannouncement payoff evidence. Beneficiaries: customers of discount model, distributors and lenders; shareholders benefit only after workingcapital and financing. Sources https://hightideinc.com/high-tide-announces-preliminary-q3-2026-guidance/ ; https://hightideinc.com/high-tide-reports-second-quarter-2026-financial-results-featuring-record-revenue-of-179-3mm-and-adjusted-ebitda-of-13-9mm/ ; https://www.sec.gov/Archives/edgar/data/910406/000119312526215679/hain-ex99_1.htm ; https://investor.roivant.com/news-events/press-releases . No valuation multiple asserted without verified sharecount/FX/debt bridge.
HITI Q2 revenue CADm179.3
HITI adjusted EBITDA CADm13.9
HITI FCF CADm1.5
HITI FCF EBITDA percent10.79
HAIN organic sales pct-6
HAIN volume mix points-11
HAIN debt USDm549
live allocation0
Sep6 research decision: retain $49.14 cash; no supported entry or reset
Startstate: no holdings or queued orders,49.14 fundcash and850.99 account equity. Goal: repeatable net pre-event gains. Bindingconstraint: independently validated executable edge. Numbered premises:1) Direct trade/monitor audit observation2880 shows nothing to exit or adjust.2) LEN issuer confirms Sep16afterclose release, notSep17call; thesis attack in182, CLI201, fixed event test210, uncertainty211, technical214 andsimulation215 fail authorization.3) ASO Sep9beforeopen leaves onlySep8 session with no tested intraday edge; ADBE andNEXT dates are documented but payoff/venue questions unresolved.4) Existing GRAL/CPRT/CHWY rejections are not changed by another calendar check.5) IONS September4 issuer8-K confirms an already-reported clinical miss, not a new pending catalyst; a biochemical response cannot substitute for clinical benefit. Sources: https://newsroom.lennar.com/2026-09-02-Lennar-Corporation-to-Broadcast-Its-Third-Quarter-2026-Earnings-Call-on-September-17%2C-2026 ; https://investors.academy.com/news-releases/news-release-details/academy-sports-outdoors-announces-second-quarter-fiscal-2026 ; https://www.adobe.com/investor-relations.html ; https://www.nextplc.co.uk/investors/reports-and-presentations/2026-27 ; https://ir.ionispharma.com/static-files/a612d86f-2531-470a-9340-5e0db04932c9 . Validity: requiring pending date, validated net edge and execution access together implies no proposal. Soundness: sources establish dates, tests establish only selected historical payoffs; absence of edge here is not proof no market edge exists. Strongest objection: LEN overlay is nominally profitable. Response: small N, uncertainty crossing0 and cost sign reversal, with whole-share price83.57 above49.14cap. Consequences of cash: no gap exposure before next02UTC run; no chance to profit from unvalidated rebound; preserved capital permits future validated entry. New monitors31-34 are research only. Existing jobs9/17 continue; no additional collection required before next02UTC research, no orders queued. ETH decision audit179 separately identifiesOct6Sepolia replacing staleSep28roadmap; crypto monitor10 owner/CIO should review, not a catalyst order. Research gaps remain recorded; no risk added to meet349.01 funding shortfall.
fund cash49.14
equity850.99
proposals0
new monitors4
LEN holdout sample10
LEN baseline return-11.92
LEN overlay return1.47
LEN stress return-1.53
live allocation0
LEN five-session path stress favors caution; not catalyst win odds
NumPy seed20260906 after two20000-sample payoff bootstraps;10000 draws from166 contiguous five-session 2026 blocks. Scale each OHLC/previous-close sequence to83.57, freeze stop81.422143,target86.791786. Opening gaps checked before intraday low/high, ambiguous both-touch stops first. Terminal5/50/95 percentiles -8.533444/-.724514/+7.272082%; stop-first60.45%,target-first30.84%,neither8.71%;95th percentile close-path drawdown8.988345%. Full code/input archive this run; source https://runway.adityaperswal.workers.dev/data/stock-bars . These are unconditional resampled path frequencies, not earnings-conditional win probabilities or executable15minute fills. Overlapping blocks are dependent; one historical regime, no new extreme gap beyond population. Prices/levels diagnostic only. Premises: current volatility permits both range boundaries in five sessions; historical paths cannot identify an event premium; fixed costed holdout is inconclusive/negative under stress. Conclusion size0, not a bearish forecast. Counterexample: a future unique catalyst could beat this distribution; requires fresh independent evidence rather than a wider target.
paths10000
blocks166
stop first percent60.45
target first percent30.84
neither percent8.71
terminal p5 percent-8.53
terminal median percent-0.72
terminal p95 percent7.27
p95 drawdown percent8.99
allocation0
LEN below major averages; range-based levels remain illustrative
Sep4 completed IEX bar, retrievedSep6, source https://runway.adityaperswal.workers.dev/data/stock-bars . Close83.57 below SMA20 85.84175,SMA50 85.62510,SMA200 97.453175; RSI14 recursive EWM44.77736;20-session return-5.24406%; realized20-session annualized volatility30.14416%. SMA ATR14 2.147857;20-session average intraday range1.80475;20-session low82.755,high89.62;mean IEX volume125430.8 shares is partial-venue volume, not consolidated liquidity. Combined indicators describe a weak trend without extreme RSI; no independently validated indicator entry. At reference83.57 a frozen one-ATR stop81.422143 and1.5ATR target86.791786 would offer nominal1.5R; target is1.785 average intraday ranges away and near overhead averages. These are diagnostic levels, not an ADJUST/PROPOSE, since no holding and no eligible rule. Do not anchor a future order to stale weekend close: recalculate at eligible entry using prior data and execution quote, preserving rule. Strong counterargument: proximity to recent lows can precede rebound; level proximity alone does not establish probability.
close83.57
ATR142.15
ADR201.8
SMA2085.84
SMA5085.63
SMA20097.45
RSI1444.78
20d return percent-5.24
illustrative stop81.42
illustrative target86.79
allocation0
LEN payoff uncertainty and live record do not support positive sizing
Python NumPy seed20260906; 20000 IID event bootstrap samples for each fixed holdout. Source price API https://runway.adityaperswal.workers.dev/data/stock-bars ; exact issuer URLs in calendar archive; own trades runway:query_trades?fund=catalyst. LEN baseline N10 mean-1.176670%,95%bootstrap mean interval[-3.803275,1.275506]%; overlay N10 mean.181465%,interval[-1.496710,1.790803]%. Fraction of resampled means positive=.17765/.5879, not forecast win probability. Overlay p=.6,W2.246256%,L2.915723% implies raw quarterKelly .0201963; preregistered uncertainty gate and negative stress mean reduce authorized size to0. Baseline raw quarterKelly-.139203 clipped0; stress overlay-.015288 clipped0. Paired gross SPY window mean+.098397%; baseline net excess-1.275067%, correlation.455788; OLS intercept-1.298713% beta1.240315,R2.207742,N10, descriptive not causal alpha or robust inference. Own three trades won0%, average loss16.380601%; two forced liquidations and one stop make this a selected mixed-catalyst sample, not setup-specific p=0 forecast. No average winning payoff can be estimated from it. RARE45.860062% loss applied to49.14 implies22.535634 loss versus8.5099 equity-risk budget; stress, not a promised worst case. Counterargument: positive overlay payoff could reflect real edge. Rebuttal:10 outcomes, bootstrap spans0, costs reverse it, and dependence may make IID interval optimistic. Need new independent prospective evidence, not parameter revision.
sample10
overlay mean percent0.18
overlay CI low-1.5
overlay CI high1.79
raw quarter Kelly0.02
authorized size0
live sample3
live win rate0
live avg loss percent16.38
RARE stress dollars22.54
equity risk dollars8.51
Frozen LEN earnings run-up fails holdout; range exits lose under cost stress
Preregistered note212 before payoff inspection; data rules note216. Source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=LEN,ADBE,ASO,SPY&timeframe=1Day&start=2021-01-01&end=2026-09-05&feed=iex&adjustment=all&limit=10000 . Exact issuer URLs/calendar and trades archived this run. Reconstructed21 completed announcements; Q4 2021 unverified notice excluded; March2022 excluded for missing ATR-window bar. Train2021-2023 N10; chronological untouched holdout2024-June2026 N10. Enter T-5 open, exit T-1 close before actual earnings release, notice strictly earlier than entry. Base fees5bp/slippage10bp each side. Baseline holdout return-11.922916%, mark-to-market DD20.464851%, wins50%, mean-1.176670%, average win2.113230%, loss4.466570%. Frozen alternative uses prior-session SMA ATR14, stop1ATR,target1.5ATR; opening gaps before intraday checks, both touches stop first. Overlay holdout return1.465552%, DD10.114489%, wins60%, mean.181465%, W2.246256%, L2.915723%. With25bp slippage plus5bp fee each side, overlay return-1.533218%, DD10.919831%, mean-.118630%. Training sensitivities T3/T5/T7 were not tested on holdout except preregistered T5 and did not select a replacement. Vectorbt from_orders, all-cash fractional sizing, agrees with direct compounded invested-cash payoffs to1e-9. Daily IEX is not consolidated or15min execution; intraday exits approximated at synthetic close slots, no claim of actual fill precision. Reconstructed announcements are primary but cannot prove absence of every intervening update. No window crosses MillroseFeb7 2025 distribution; structural change still limits pooling. Reject live risk: uncertainty and costs fail, whole share also unaffordable.
return1.47
drawdown10.11
win rate60
sample10
baseline return-11.92
stress return-1.53
average win percent2.25
average loss percent2.92
mean percent0.18
training sample10
live allocation0
LEN CLI momentum baseline rejected; not an earnings-edge estimate
Executed node /app/agent/dist/backtest.js --symbols LEN --strategy momentum --lookback 5 --days 2000 --stop-pct 3 --target-pct 4.5. IEX1373bars/223trades. Return-33.059019%, drawdown46.427112%, wins35.426009%, average trade-.135762%, buy-and-hold-5.836620%. Source https://runway.adityaperswal.workers.dev/data/stock-bars . Engine inspection /app/agent/src/backtest/engine.ts: signal-close entries, exact price stop/target with no opening-gap treatment, no cost/holdout split. This is required CLI baseline, not independent support for a catalyst proposal. Rule and price adjustment differ from frozen event study, so difference in output will not isolate a single cause. Reject CLI as trading evidence even before adding costs.
return-33.06
drawdown46.43
win rate35.43
sample223
bars1373
average trade percent-0.14
Lennar bear case: maintaining volume does not guarantee margin recovery
Start: $49.14 cash, no holding; goal a profitable pre-release trade, binding constraint validated payoff. Premises: (1) June11 issuer figures in observation2902 show pricing concessions alongside delivery growth. (2) Q3 guidance assumes better gross margin and overhead absorption. (3) A dated release is not a positive surprise. Source https://newsroom.lennar.com/2026-06-11-Lennar-Reports-Second-Quarter-2026-Results . Bear inference: affordability pressure can consume cost savings, so volume survives while cash returns disappoint. Strong counterargument: faster turns, lower costs and limited owned land can improve capital efficiency before demand recovers. Both can hold: sequential improvement and year-over-year deterioration use different periods. Who benefits: buyers receive incentives, lenders/land banks earn financing returns, issuer protects throughput; stockholders need residual cash, not merely homes delivered. First order weaker affordability requires concessions; second order concession costs reduce earnings and may affect subcontractor demand; third order reduced capital returns constrain buybacks and land commitments. Reverse chain: lower financing costs -> fewer concessions -> improved cash returns, but no verified imminent rate move assumed. Valid conclusion is watch rather than a directional short or approval to buy. Missing September orders, cancellations, current mortgage terms and updated balance sheet prevent a present valuation claim.
Q2 gross margin percent15.6
year-ago gross margin percent17.8
Q3 guided gross margin percent16
Q2 incentive percent12.9
allocation0
Sepolia date audit: newer developer decision supersedes stale roadmap; no price edge
Start state49.14 catalyst cash; goal repeatable net gains; binding constraint independently validated executable edge. This is a trading audit of saved research, not a fresh research strategy or backtest. Numbered premises: (1) Direct fund query_trades returns only3 closed trades and list_monitors13 armed, none due before next Sep6 00UTC run; no exit/adjustment obligation. (2) Frozen cost-adjusted chronological tests132/113/38 remain negative: GRAL-36.2152% N13, CPRT-4.2620% N5, CHWY-1.719988% N6. Recomputed clipped quarterKelly0 all, full details observation2831 if assigned sequentially; metric Saved holdout payoff and gap-risk arithmetic audit is authoritative lookup. Raw data source https://runway.adityaperswal.workers.dev/data/stock-bars . (3) Fresh regulator/issuer page checks retain GRAL Sep23 panel09–18ET and Sep14 conference11:30EDT: https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-23-2026-molecular-and-clinical-genetics-panel-medical-devices-advisory-committee-meeting ; https://investors.grail.com/events/event-details/morgan-stanley-24th-annual-global-healthcare-conference . Returned FDA page shows no briefing link; not a claim none exists elsewhere. (4) Job notes176/181/186 repeat already-reviewed IONS news, not independent evidence. No recorded adopted rule supports another name. Conclusion zero proposals; maintain all cash and existing research monitors/jobs. Validity: numerical edge is necessary under mandate, so unsupported entries cannot follow merely from confirmed dates. Soundness: small selected samples, generic GRAL rather than panel-event strategy, daily fill approximations and forced-liquidation-biased live record limit inference; does not prove all run-ups fail. Strongest counterargument: upcoming optimism could rally stocks; true but no measured positive executable payoff provided. Evidence needed to change size: separately preregistered positive net event holdout, valid current entry window, complete pipeline and feasible venue exits. Who benefits: issuer optimism may help financing; fund benefits only if net realizable payoff exceeds costs. Consequence chain: new briefing may change expectations -> gaps can bypass planned stops -> losses reduce deployable capital; this is a conditional chain, not forecast. Observed RARE gap stress22.5356 on fullbook exceeds8.5099 risk budget; not a future loss bound. No fresh indicators, simulation or test rerun warranted with no eligible entry or changed rule. Gaps: not exhaustive issuer/docket surveillance; original GRAL scientific issues remain from note170; no15minute execution validation. No orders placed, no duplicate monitors required, no other fund actions.
Question: Can Galleri's September 23 FDA panel support a defensible pre-event run-up despite conflicting clinical endpoints? Conclusion: no allocation on the evidence available; this is not a prediction of rejection or a falling stock.
Numbered premises:
1. FDA confirms the September 23 advisory PMA meeting. Its August 10 notice plans background materials before the meeting but provides no earliest publication guarantee. The issuer also confirms a September 14 11:30 EDT presentation. An exit tied only to September 23 would miss earlier information risk. Sources: https://www.federalregister.gov/documents/2026/08/10/2026-16245/molecular-and-clinical-genetics-panel-of-the-medical-devices-advisory-committee-notice-of-meeting ; https://investors.grail.com/events/event-details/morgan-stanley-24th-annual-global-healthcare-conference .
2. NHS primary stage III/IV reduction failed; nominal stage IV improvement does not establish mortality benefit. Performance-focused PMA evidence and an updated-version bridge mean failure does not mechanically determine FDA's judgment. Current registry and sponsor slides disclose different populations, safety ascertainment windows and a post-lock serious workup event. Analyses126/151 and note165 retain the p-value discrepancy (.6234 versus .6324) without changing the non-significant conclusion. Sources: https://clinicaltrials.gov/api/v2/studies/NCT05611632 ; https://clinicaltrials.gov/api/v2/studies/NCT05155605 ; https://investors.grail.com/static-files/995005e4-2c8e-4a02-bef0-400403856cc7 .
3. Cash and positive adjusted lab gross profit support continued development, but cash burn, dilution and the impaired Samsung commercial asset prevent treating approval as immediate profit. Analysis131 uses the June 30 filing: https://www.sec.gov/Archives/edgar/data/1699031/000162828026054307/gral-20260630.htm .
4. Preregistered generic price diagnostic132 lost36.215% net in 13 chronological holdout trades: p30.769%, average win7.549%, average loss7.741%, quarter-Kelly0. This does not test the panel-specific anomaly; a comparable historical panel/first-briefing sample is missing. Source: https://runway.adityaperswal.workers.dev/data/stock-bars .
5. Current trigger is false; one $80.34 share exceeds the $49.14 book. Fractions cannot provide the required overnight exit access. No live holdings or queued orders need review or adjustment.
Validity: under the required numerical edge and execution rules, these premises imply zero size. Soundness is limited by selected historical prices, daily fills, small samples, missing original SAP/absolute stage counts and FDA bridging review. Strongest counterargument: useful detection and regulatory optimism could produce a rally before revenues. True; it does not supply an independently measured payoff distribution.
Prior remains uncalibrated for approval. New FDA bridging/safety evidence could change scientific WATCH status; trading eligibility stays0 until an independently frozen event rule has positive net evidence (including a dependence-aware lower mean bound above0), valid whole-share sizing and actual venue exits. More repeated headlines change allocation by$0.
Monitor25 now covers September14; retain panel monitor23 and verified research collector17. No duplicate collector, no other fund actions, no orders. Full91-part data/code archive verified exactly, note169. Final lessons recorded in the finish phase. Research sources stopped changing the no-allocation conclusion; unresolved gaps are named rather than guessed. About14minutes used of42 planned, within45 ceiling; final5-minute allowance preserved and entered early.
cash49.14
holdout_return-36.22
holdout_drawdown39.02
holdout_sample13
win_probability0.31
average_win7.55
average_loss7.74
quarter_kelly0
current_signal0
whole_share_capacity0
proposed_notional0
archive_parts91
Galleri consequence chain: public evidence moves first, coverage and cash follow separately